mdlinx mdlinx
Latest (288) Full Text Articles (9654) Focus on GERD & PUD Article Summary

Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer
Cancer,  Clinical Article

Stevenson JP et al. – Combined bevacizumab, pemetrexed, and carboplatin followed by maintenance bevacizumab was well tolerated and displayed remarkable activity in patients with previously untreated, advanced, nonsquamous nonsmall cell lung cancer.

Methods
  • Previously untreated patients with advanced, nonsquamous nonsmall cell lung cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1 received bevacizumab 15mg/kg, pemetrexed 500mg/m2 and carboplatin at an area under the concentration-time curve of 6 intravenously on day 1 every 21days.
  • Responding or stable patients who completed 6 cycles then received bevacizumab maintenance every 21days until disease progression.

Results
  • In total, 43 patients (40 who were evaluable for response) were entered on the study.
  • Treatment-related grade 3/4 toxicities were low and included febrile neutropenia (2%), neutropenia (28%), anemia (18%), thrombocytopenia (11%), hypertension (7%), epistaxis (5%), venous thrombosis (8%), dyspnea (7%), rectovaginal fistula (2.3%), infusion reaction (2%), and cerebrovascular event (2%).
  • One patient died from complications of venous thromboembolism and cerebrovascular accident after Cycle 2.
  • Minimal clinically significant toxicity occurred during maintenance bevacizumab.
  • Two complete responses (5%) were observed, and 17 patients (42%) had a partial response.
  • Fifteen patients (38%) displayed disease stability.
  • The overall disease control rate was 85%.
  • At a median follow-up of 15.8months, the median progression-free survival was 7.1months (95% confidence interval, 5.9-8.3months), and the median overall survival was 17.1months (95% confidence interval, 8.8-25.5months).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

Last month's top read Top Articles of 2013

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore

Other Topics in Internal Medicine

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close